Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valpromide is a carboxamide derivative of valproic acid and acts as a prodrug for valproic acid. It is used primarily in the treatment of epilepsy and as an adjunct therapy for psychomotor agitation, depression, and manic episodes associated with bipolar disorder. After oral administration, it is rapidly metabolized (about 80%) to valproic acid but also possesses intrinsic anticonvulsant activity. Its mechanism of action involves increasing GABA levels in the brain and altering neuronal membrane conductance, contributing to its antiepileptic and mood-stabilizing effects. Valpromide inhibits liver microsomal epoxide hydrolase much more potently than valproic acid, which can lead to significant drug interactions (notably with carbamazepine). It may provide more stable plasma levels than other forms of valproate but shares similar safety concerns during pregnancy[1][2][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Valpromide.